414
Participants
Start Date
August 31, 2001
Study Completion Date
February 28, 2007
Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)
treatment with 90 Yttrium-labeled anti CD 20 antibody
no treatment
no treatment
Brussels
Lausanne
Geneva
Antwerp
Copenhagen
Leuven
Bern
Aarau
Yvoir
Bellinzona
Bruges
Zurich
Ghent
Sankt Gallen
Torino
Rozzano
Hamburg
Milan
Milan
Milan
Besançon
Madrid
Madrid
Málaga
Bordeaux
Rennes
Tours
Salamanca
Göttingen
Grenoble
Bologna
Düsseldorf
Gothenburg
Valencia
Münster
Angers
Cologne
Pisa
Lille
Hamm
Strasbourg
Lyon
Pierre-Bénite
San Giovanni Rotondo
Le Mans
Tübingen
Paris
Rouen
Napoli
München
Augsburg
Palermo
Créteil
Edmonton
Vancouver
Hamilton
Ottawa
Toronto
Toronto
Montreal
Montreal
Aarhus
Dresden
Roma
Amersfoort
Amsterdam
Amsterdam
Eindhoven
Enschede
Groningen
Leiden
Maastricht
Nijmegen
Rotterdam
The Hague
Utrecht
Zwolle
Oslo
Tromsø
Coimbra
Lisbon
Lisbon
Porto
L'Hospitalet de Llobregat
Barcelona
Barcelona
Umeå
Uppsala
Glasgow
London
London
Manchester
Newcastle upon Tyne
Plymouth
Surrey
Lead Sponsor
Bayer
INDUSTRY